dc.contributor.author
Klier, John
dc.contributor.author
Bartl, Carolin
dc.contributor.author
Geuder, Sabine
dc.contributor.author
Geh, Katharina J.
dc.contributor.author
Reese, Sven
dc.contributor.author
Goehring, Lutz S.
dc.contributor.author
Winter, Gerhard
dc.contributor.author
Gehlen, Heidrun
dc.date.accessioned
2019-11-26T10:49:33Z
dc.date.available
2019-11-26T10:49:33Z
dc.identifier.uri
https://refubium.fu-berlin.de/handle/fub188/26002
dc.identifier.uri
http://dx.doi.org/10.17169/refubium-25760
dc.description.abstract
Introduction
Equine asthma represents a naturally occurring animal model for human allergic neutrophilic asthma. Inhalative nanoparticle‐bound cytosine‐phosphate‐guanosine (CpG‐GNP) immunotherapy, independent of specific allergens, has already shown promising clinical and immunological results in previous studies and offers the possibility to treat the underlying cause of the disease. This study analyses the relationship between dose and response, and evaluates a possible long‐term effect.
Methods
In the prospective, randomised, double‐blind clinical field study, 29 horses suffering from equine asthma received 10 inhalation treatments with either 187.5 µg CpG‐GNP (CpG single dose [CpGsd]; n = 11), 375 µg CpG‐GNP double dose (CpG double dose [CpGdd]; n = 9) (q48h for 20 days) or 1600 µg beclomethasone (n = 9) (q24h for 10 days). Each horse was examined three times: before the treatment (I), immediately after the 10 inhalations (II), and 8 weeks after the final inhalation (III). The three groups were compared according to clinical and laboratory parameters. The study examined the sustainability of the long‐term effect of the treatment after 8 weeks, as well as the tolerability of the formula as a double dose.
Results
The CpGsd resulted in a significant improvement in 82% of the parameters, the CpGdd in 72%. In the long‐term evaluation, the CpGsd showed a significant improvement in 100% of the parameters in comparison to the initial values, the CpGdd in 67%. On the immunological level, the bronchoalveolar lavage revealed a significant reduction of IL‐4, IL‐8, and interferon‐γ.
Conclusion
Both CpG groups displayed significant improvements in clinical and laboratory parameters, especially regarding the long‐term effect of CpGsd. Doubling the CpG dose did not result in any improvement in comparison to the original single dose. On the immunological level, an anti‐inflammatory, as well as an immunomodulatory effect, apart from a Th2‐dominated immune response, could be observed. This immunomodulatory inhalation treatment could indicate a new possibility for human allergic asthma therapy.
en
dc.format.extent
20 Seiten
dc.rights.uri
https://creativecommons.org/licenses/by/4.0/
dc.subject
allergic asthma
en
dc.subject
extrinsic asthma
en
dc.subject
neutrophilic asthma
en
dc.subject.ddc
600 Technik, Medizin, angewandte Wissenschaften::610 Medizin und Gesundheit::616 Krankheiten
dc.subject.ddc
500 Naturwissenschaften und Mathematik::590 Tiere (Zoologie)::599 Mammalia (Säugetiere)
dc.title
Immunomodulatory asthma therapy in the equine animal model: A dose‐response study and evaluation of a long‐term effect
dc.type
Wissenschaftlicher Artikel
dcterms.bibliographicCitation.doi
10.1002/iid3.252
dcterms.bibliographicCitation.journaltitle
Immunity, Inflammation and Disease
dcterms.bibliographicCitation.number
3
dcterms.bibliographicCitation.pagestart
130
dcterms.bibliographicCitation.pageend
149
dcterms.bibliographicCitation.volume
7
dcterms.bibliographicCitation.url
https://doi.org/10.1002/iid3.252
refubium.affiliation
Veterinärmedizin
refubium.affiliation.other
Klinik für Pferde
refubium.funding
DEAL Wiley
refubium.note.author
Die Publikation wurde von der Freien Universität Berlin finanziert.
refubium.resourceType.isindependentpub
no
dcterms.accessRights.openaire
open access
dcterms.isPartOf.eissn
2050-4527